Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4621)	6/29/1998 11:20:00 PM
From: Steve Fancy	Respond to of 6136

Bhag, I probably shouldn't open my mouth on issues I know little about, but I thought Remune was in phase III trials and will be submitted to FDA for approval by April '99. I also get the distinct impression the world is less than convinced on AG3340. Although not yet invested, I am excited over the Entremed story. This could be an incredible breakthrough for cancer patients. I wouldn't be surprised to see a drug of this potential caliber moved right on through the approval process. If the story unfolds as successfully as it sounds, the public may demand it. sf